INVESTOR RELATIONS

Investor relations

PRESS RELEASES

Redeye Growth Day takes place on June 2 in Stockholm and will be a combination of a digital platform and live presentations. Lipum is "In Focus"...
CEO Einar Pontén comments: “More progress was made in the preparations ahead of clinical trials. In parallel, and in accordance with our strategy...
Pelago Bioscience AB is a fast-growing Swedish company, based in Solna, with bioanalytical expertise and services for drug discovery and development. Pelago...
Lipum is member of the consortium together with both industry and academic partners. The project is led by the Cardiovascular Research Centre (CVRC) at...
The aim of Annual European Congress of Rheumatology EULAR 2022 is to provide a forum of the highest standard for scientific (both clinical and basic)...
2022-03-25 06:00 Lipum AB – Year-end report 2021 Regulatory
CEO Einar Pontén comments: “The last quarter of the year was largely characterized by the fact that we completed activities that constitute...
Lipum AB and QPS The Netherlands BV are pleased to announce a collaboration on the first-in-human study of SOL-116 with the aim of becoming a new treatment...
Lipum's biological drug candidate SOL-116 has successfully been manufactured under the regulations that apply to Good Manufacturing Practice (GMP). The...
2022-02-02 13:00 Lipum recruits scientist
Lipum's development work is in an intensive phase and an initial clinical phase 1 study is being prepared. Preclinical studies have previously shown promising...
2021-12-22 13:00 Lipum AB - report from extra general meeting Regulatory
Decision on the introduction of incentive programs for employees and consultants The meeting resolved that the program shall consist of a maximum of 72,500...

INVESTOR RELATIONS

Investor relations